The expression of a tumor suppressor gene JDP2 and its prognostic value in hepatocellular carcinoma patients.
The c-Jun dimerization protein 2 (JDP2) belongs to the activator protein-1 (AP-1) family and functions as a repressor of the AP-1 complex by dimerizing with other c-Jun proteins. Thus, JDP2 plays an important role in the repression of AP-1-driven biological processes, such as differentiation and proliferation. Recent studies have suggested that JDP2 may function as a tumor suppressor through its suppressive action against the AP-1 complex, which is known to drive oncogenic signals in several human malignancies. In this study, we used immunohistochemistry to examine the JDP2 expression in 211 cases of hepatocellular carcinoma (HCC) and analyzed the potential link of JDP2 expression to the clinicopathological features of HCC patients. Clinical parameter analysis showed that high expression of JDP2 was significantly correlated with smaller tumor size (P=.002) and early stage HCC (P=.039). Moreover, Kaplan-Meier survival analysis showed that high expression of JDP2 was significantly associated with better survival in HCC patients (P=.006). Taken together, our results showed that JDP2 may serve as a tumor suppressor in HCC and could therefore serve as a good prognostic marker for patients with HCC.
School of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan; Department of General Surgery, Changhua Christian Hospital, Changhua, 50006, Taiwan; Transplantation Center, Third Xiangya Hospital of Central South University, Changsha, 410008, China.
Yao-Li
YL
Chen
Graduate Institute of Integrated Medicine, China Medical University, Taichung, 40402, Taiwan; Institute of Molecular and Genomic Medicine, National Health Research Institute, Miaoli, 35053, Taiwan.
Shih-Hsuan
SH
Chan
Department of General Surgery, Changhua Christian Hospital, Changhua, 50006, Taiwan.
Ping-Yi
PY
Lin
Department of Pathology, Show Chwan Memorial Hospital, Changhua, 50008, Taiwan; School of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei City, 24205, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, 70456, Taiwan. Electronic address: chu.peiy@msa.hinet.net.
Pei-Yi
PY
Chu
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012097:Repressor Proteins / Q000032:analysis*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden; D025521:Tumor Suppressor Proteins / Q000032:analysis*
D014408:Biomarkers, Tumor; C491387:JDP2 protein, human; D012097:Repressor Proteins; D025521:Tumor Suppressor Proteins
Hepatocellular carcinoma; Immunohistochemistry; JDP2; Prognosis; Tumor suppressor gene